Abstract
The rapid emergence of drug-resistant malaria parasites during the course of an infection remains a major challenge for providing accurate treatment guidelines. This is particularly important in cases of malaria treatment failure. Using a previously well-characterized case of malaria treatment failure, we show the utility of using next-generation sequencing for early detection of the rise and selection of a previously reported atovaquone-proguanil (malarone) drug resistance-associated mutation.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antimalarials / therapeutic use
-
Atovaquone / therapeutic use
-
Cytochromes b / genetics*
-
Drug Combinations
-
Drug Resistance / genetics*
-
Gene Expression
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Malaria, Falciparum / drug therapy
-
Malaria, Falciparum / parasitology
-
Male
-
Mutation*
-
Nigeria
-
Plasmodium falciparum / drug effects
-
Plasmodium falciparum / genetics*
-
Plasmodium falciparum / isolation & purification
-
Proguanil / therapeutic use
-
Protozoan Proteins / genetics*
-
Travel
-
Treatment Failure
-
United States
Substances
-
Antimalarials
-
Drug Combinations
-
Protozoan Proteins
-
atovaquone, proguanil drug combination
-
Cytochromes b
-
Proguanil
-
Atovaquone
Grants and funding
We acknowledge support from the Advanced Molecular Detection Initiative at the CDC. E.T. is supported by the Atlanta Research and Education Foundation.